Cediranib

Generic Name: Cediranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇FN_₄O_₃

CAS Number: 288383-20-0

Unique Ingredient Identifier: NQU9IPY4K9

Background: The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Indication: For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: cediranib maleate

First Posted Date: 2006-03-22

Last Posted Date: 2013-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00305656

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer
Clear Cell Renal Cell Carcinoma

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2006-03-17

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00303862

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00278343

Locations: 🇺🇸
City of Hope Medical Group Inc, Pasadena, California, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 25 locations

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Stage II Ovarian Epithelial Cancer
Fallopian Tube Cancer
Primary Peritoneal Serous Adenocarcinoma
Recurrent Ovarian Epithelial Cancer
Stage I Ovarian Epithelial Cancer

Interventions: Drug: cediranib maleate

First Posted Date: 2006-01-11

Last Posted Date: 2015-11-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00275028

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis
Other: pharmacogenomic studies

First Posted Date: 2005-10-27

Last Posted Date: 2014-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00245063

Locations: 🇺🇸
City of Hope, Duarte, California, United States

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Phase 2

Completed

Conditions: Recurrent Breast Cancer
Male Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-27

Last Posted Date: 2015-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00244881

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Small Size
Extraocular Extension Melanoma
Stage IV Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Acral Lentiginous Malignant Melanoma
Intraocular Melanoma
Iris Melanoma
Lentigo Maligna Malignant Melanoma
Recurrent Melanoma
Stage, Intraocular Melanoma

Interventions: Drug: cediranib maleate

First Posted Date: 2005-10-21

Last Posted Date: 2018-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00243061

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma
Epithelial Mesothelioma

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-21

Last Posted Date: 2018-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00243074

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-13

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00238394

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Drug: Cediranib Maleate
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2005-09-28

Last Posted Date: 2016-02-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00227760

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy